Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Among 10 C
North America is the leading regional market primarily because of the rising prevalence of obesity and Type 2 diabetes in this region
But theres no guarantee because your body chemistry is different
Metabolism & Elimination Both peptides undergo similar metabolic pathways despite their structural differences: GLP1 metabolism: Proteolytic cleavage of the peptide backbone across multiple tissues Sequential beta-oxidation of the fatty acid side chain No organ-specific metabolism with degradation occurring in multiple tissues simultaneously Six identified metabolites in human plasma, with metabolite P3 comprising approximately 7.7% of circulating drug-related material Intact peptide predominance with 69-83% of circulating material remaining as intact GLP1 Cagrilintide metabolism: Similar proteolytic pathways to GLP1 due to peptide structure Fatty acid chain processing through beta-oxidation mechanisms Albumin-mediated protection reducing enzymatic access to the peptide backbone Reversible albumin binding allowing gradual release and metabolism No specific organ predominance for metabolic clearance The remarkably similar half-lives of both peptides (159-195 hours for cagrilintide, 145-165 hours for GLP1) enable synchronized pharmacokinetic profiles ideal for fixed-dose combination therapy
The specific differences in their efficacy in reducing EAT volume, improving EAT inflammatory status, and ultimately preventing and treating AF remain uncleara gap that greatly limits clinicians' ability to individualize drug selection based on patient-specific conditions
